Cytidine Deaminase Residual Activity in Serum Is a Predictive Marker of Early Severe Toxicities in Adults After Gemcitabine-Based Chemotherapies
- 1 January 2010
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (1), 160-165
- https://doi.org/10.1200/jco.2009.24.4491
Abstract
Purpose: Anticipating toxicities with gemcitabine is an ongoing story, and deregulation in cytidine deaminase (CDA) could be associated with increased risk of developing early severe toxicities on drug exposure. Patients and Methods: A simple test to evaluate CDA phenotypic status was first validated in an animal model investigating relationships between CDA activity and gemcitabine-related toxicities. Next, relevance of this test as a marker for toxicities was retrospectively tested in a first subset of 64 adult patients treated with gemcitabine alone, then it was tested in a larger group of 130 patients who received gemcitabine either alone or combined with other drugs and in 20 children. Additionally, search for the 435 T>C, 208 G>A and 79 A>C mutations on the CDA gene was performed. Results: In mice, CDA deficiency impacted on gemcitabine pharmacokinetics and had subsequent lethal toxicities. In human, 12% of adult patients experienced early severe toxicities after gemcitabine administration. A significant difference in CDA activities was observed between patients with and without toxicities (1.2 ± 0.8 U/mg v 4 ± 2.6 U/mg; P < .01). Conversely, no genotype-to-phenotype relationships were found. Of note, the patients who displayed particularly reduced CDA activity all experienced strong toxicities. Gemcitabine was well tolerated in children, and no CDA deficiency was evidenced. Conclusion: Our data suggest that CDA functional testing could be a simple and easy marker to discriminate adult patients at risk of developing severe toxicities with gemcitabine. Particularly, this study demonstrates that CDA deficiency, found in 7% of adult patients, is associated with a maximum risk of developing early severe toxicities with gemcitabine.Keywords
This publication has 22 references indexed in Scilit:
- Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantationJournal of Gastroenterology and Hepatology, 2009
- Prognostic Factors in Japanese Patients with Advanced Pancreatic Cancer Treated with Single-agent Gemcitabine as First-line TherapyJapanese Journal of Clinical Oncology, 2008
- Correlation Between Cytidine Deaminase Genotype and Gemcitabine Deamination in Blood SamplesNucleosides, Nucleotides and Nucleic Acids, 2008
- Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin–Treated Advanced Non–Small Cell Lung Cancer PatientsClinical Cancer Research, 2008
- High-performance liquid chromatographic method for the determination of gemcitabine and 2′,2′-difluorodeoxyuridine in plasma and tissue culture mediaJournal of Chromatography B, 2006
- Gemcitabine Pharmacogenomics: Cytidine Deaminase and Deoxycytidylate Deaminase Gene Resequencing and Functional GenomicsClinical Cancer Research, 2006
- Severe Drug Toxicity Associated with a Single-Nucleotide Polymorphism of the Cytidine Deaminase Gene in a Japanese Cancer Patient Treated with Gemcitabine plus CisplatinClinical Cancer Research, 2005
- Epimer interconversion, isomerization, and hydrolysis of tetrahydrouridine: Implications for cytidine deaminase inhibitionJournal of Pharmaceutical Sciences, 2003
- A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivityPharmacogenetics, 2003
- A stochastic model describes the heterogeneous pharmacokinetics of cyclosporin.Journal of Pharmacokinetics and Pharmacodynamics, 2001